United Therapeutics Co. (NASDAQ:UTHR) Director Sells $980,532.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $272.37, for a total transaction of $980,532.00. Following the completion of the transaction, the director now directly owns 130 shares of the company’s stock, valued at $35,408.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Trading Up 0.5 %

Shares of UTHR stock opened at $276.44 on Thursday. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $279.98. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The firm’s 50 day moving average is $245.78 and its 200 day moving average is $233.38. The stock has a market capitalization of $12.26 billion, a P/E ratio of 13.07 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The company had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. During the same quarter last year, the company posted $4.86 earnings per share. The firm’s quarterly revenue was up 33.7% on a year-over-year basis. Research analysts expect that United Therapeutics Co. will post 24.2 earnings per share for the current year.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of UTHR. Rise Advisors LLC purchased a new position in shares of United Therapeutics in the 1st quarter worth $32,000. GAMMA Investing LLC purchased a new position in shares of United Therapeutics in the 4th quarter worth $43,000. Benjamin F. Edwards & Company Inc. grew its stake in shares of United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after buying an additional 117 shares in the last quarter. C M Bidwell & Associates Ltd. purchased a new position in shares of United Therapeutics in the 3rd quarter worth $91,000. Finally, Janiczek Wealth Management LLC grew its stake in shares of United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after buying an additional 84 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of research reports. Oppenheimer increased their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. Wedbush reaffirmed an “outperform” rating and set a $308.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. HC Wainwright reaffirmed a “buy” rating and set a $300.00 target price on shares of United Therapeutics in a research note on Thursday, May 2nd. Wells Fargo & Company raised their target price on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. Finally, StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 16th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $309.44.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.